laitimes

Huihai Pharmaceutical and other monopoly markets were fined 1.2 billion, 100 times higher than imported drugs, and the huge profits were amazing

author:Ode to incense

Foreword: "The world with good order in my mind is a world in which medical discoveries are not protected by privilege, and no one can rely on life and death to make huge profits. —Ingla Gandhi

On December 22, the Shanghai Municipal Administration for Market Regulation fined and confiscated 1.219 billion yuan to Shanghai Pharmaceutical First Biochemical, Wuhan Huihai Pharmaceutical Co., Ltd., Wuhan Kede Pharmaceutical Co., Ltd., and Hubei Minkang Pharmaceutical Co., Ltd.

Huihai Pharmaceutical and other monopoly markets were fined 1.2 billion, 100 times higher than imported drugs, and the huge profits were amazing

These four companies, taking advantage of their monopoly position in the Chinese market and polymyxin sulfate B for injection, sold the sky-high price of similar drugs dozens or hundreds of times higher than that of similar foreign drugs.

Huihai Pharmaceutical and other monopoly markets were fined 1.2 billion, 100 times higher than imported drugs, and the huge profits were amazing

The audacious and insatiable shameless behavior of these four companies has aroused the anger of the majority of netizens.

Among these four companies, Shanghai Pharmaceutical Biochemical is a foundry, and the other three are all affiliated enterprises of Wuhan Huihai with the same investor.

Huihai Pharmaceutical and other monopoly markets were fined 1.2 billion, 100 times higher than imported drugs, and the huge profits were amazing

A.Celli China

In 2010, Wuhan Huihai signed the API Supply Agreement with Aceris of Denmark and became the agent of Aceris of Denmark in the Chinese market.

In 2016, Wuhan Huihai discovered the huge price difference between polymyxin B sulfate API and finished drug, and obtained the exclusive distribution right of polymyxin B sulfate API in China by bribing Danish A.C. Aceli Chinese executives to polymyxin B sulfate API.

In order to cover up people's eyes, Wuhan Huihai Company registered two other companies, that is, the other two on the punishment list, forming the illusion that three agents of polymyxin B sulfate API. After that, it entrusted Shanghai Shanghai Pharmaceutical Biochemical Production, and monopolized the production and sales of polymyxin B sulfate in the country.

Huihai Pharmaceutical and other monopoly markets were fined 1.2 billion, 100 times higher than imported drugs, and the huge profits were amazing

Yacelli China, conference site

Under the influence of profit, Wuhan Huihai Company used its exclusive pricing power to sell raw materials that cost more than ten yuan at a violent high price of several thousand yuan. It has added a huge burden to the health care of the whole country.

For such a black-hearted businessman, the punishment only accounted for 11% of the previous year's sales, which is really not enough to make the people angry, such a company should be allowed to go bankrupt, and investors can never get involved in the pharmaceutical manufacturing and circulation industry.

Let's review the famous words of Mrs. Ingla Gandhi and awaken the conscience of our countrymen!

"I have in mind a world of good order, a world where medical discoveries are not protected by privilege, and no one can make huge profits from the events of life and death. ”

May the realm of life and death be forever driven out of profiteering!

Read on